LXRX
LEXICON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.50
+2.42%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.51
From 52W high−43.36%
Volume772415.00
Market cap$665.34M
P/E (TTM)—
P/S (TTM)16.0x
Div yield—
Key dataNov 4, 2026
Open
$1.51
From 52W high
−43.36%
Volume
772415.00
Market cap
$665.34M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.2x
P/E (TTM)
—
RSI (14)
34.4
MomentumView details →
1D Return
+2.42%
YTD Return
+27.37%
SummaryUpdated Jun 1, 2026
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company founded in 1995 and headquartered in The Woodlands, Texas. The company went public in 2000 and focuses on discovering, developing, and commercializing small molecule pharmaceutical products primarily for cardiovascular, metabolic, and neurological conditions. Lexicon has evolved from a drug discovery company into a commercial-stage biopharmaceutical company with one approved product and multiple late-stage pipeline candidates targeting significant unmet medical needs.
Similar companies
Latest newsMore news →
LEXICON PHARMACEUTICALS, INC. announced that it will release its third-quarter 2026 financial results before market open on November 5, 2026, and hold a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a business update.6d agoLEXICON PHARMACEUTICALS, INC. highlighted findings from two newly reported preclinical studies showing favorable effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy and on platelet activity and thrombus formation.14d ago